RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Lowers Price Target to $133
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowers the price target from $136 to $133.
October 04, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Neurocrine Biosciences but has lowered the price target from $136 to $133, indicating a slightly less optimistic outlook.
The lowering of the price target by RBC Capital suggests a slightly less optimistic view on Neurocrine Biosciences' future performance, which could lead to a short-term negative impact on the stock price. The maintained Sector Perform rating indicates that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100